Lemalesomab
From Wikipedia the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | NCA-90 (granulocyte antigen) |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.[1][2]
References
[edit]- ^ "International Nonproprietary Names (INN) for Pharmaceutical Substances Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4): 260. 2000.
- ^ Pelletier JP (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic concepts in transfusion medicine. Philadelphia: Elsevier. p. 296. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. S2CID 213508934.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |